{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:19:32Z","timestamp":1787008772941,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Homozygous familial hypercholesterolaemia (HoFH) is characterized by markedly elevated LDL cholesterol (LDL-C). Most individuals with HoFH do not reach LDL-C targets with standard lipid-lowering therapies (LLTs). However, LDL receptor (LDLR)-independent LLTs have demonstrated effectiveness in these individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This post hoc subanalysis examined concomitant use of two LDLR-independent treatments, lipoprotein apheresis (LA) and evinacumab (an angiopoietin-like 3 inhibitor), in participants with HoFH from three clinical studies of evinacumab. We included participants with HoFH who received 15\u2005mg\/kg evinacumab in any Regeneron-sponsored clinical study. Participants were stratified by concurrent LA treatment at study baseline. The primary outcome was the mean change in LDL-C from baseline to Week 24. Other outcomes included change in LA frequency and safety. Outcomes were examined descriptively. A total of 138 participants were included, 59 (43%) undergoing LA at baseline and 79 (57%) not undergoing LA at baseline. From baseline to Week 24, mean (standard deviation) LDL-C was reduced in participants undergoing LA at baseline [\u221242.9% (23.8)] and those who were not [\u221250.8% (30.5)]. Reductions in LDL-C in both subgroups were observed across all examined timepoints. Among those undergoing LA at baseline, LA frequency was reduced in 17 (29%) participants and increased in 2 (3%) participants. Evinacumab was well-tolerated in both subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated considerable benefit of evinacumab for individuals with HoFH, with or without concurrent LA. Evinacumab appeared to lessen LA burden for some individuals. This analysis suggests that LA and evinacumab can be combined without compromising efficacy or safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag182","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:50:31Z","timestamp":1774529431000},"source":"Crossref","is-referenced-by-count":2,"title":["Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia"],"prefix":"10.1093","author":[{"given":"Patrick M","family":"Moriarty","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Kansas Medical Center , Kansas City, KS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6223-5671","authenticated-orcid":false,"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2542-9930","authenticated-orcid":false,"given":"Richard","family":"Godin","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. , 777 Old Saw Mill River Rd, Tarrytown, NY 10591 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1725-5587","authenticated-orcid":false,"given":"Alpana","family":"Waldron","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. , 777 Old Saw Mill River Rd, Tarrytown, NY 10591 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0633","authenticated-orcid":false,"given":"Robert S","family":"Rosenson","sequence":"additional","affiliation":[{"name":"Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , NewYork, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Qiao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cardiology Atherosclerosis Research Lab, University of Washington School of Medicine , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-6795","authenticated-orcid":false,"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. , 777 Old Saw Mill River Rd, Tarrytown, NY 10591 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J","family":"Raal","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"Clinical Lipidology and Rare Lipid Disorders Unit, Community Gene Medicine Center, Department of Medicine, Universit\u00e9 de Montr\u00e9al and ECOGENE-21 Clinical and Translational Research Center , Chicoutimi, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2026041214411615300_zwag182-B1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"2026041214411615300_zwag182-B2","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"2026041214411615300_zwag182-B3","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026041214411615300_zwag182-B4","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 inhibitors: mechanism of action, efficacy, and safety","volume":"19","author":"Roth","year":"2018","journal-title":"Rev Cardiovasc Med"},{"key":"2026041214411615300_zwag182-B5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/CIRCRESAHA.118.313171","article-title":"Lipid-lowering agents","volume":"124","author":"Hegele","year":"2019","journal-title":"Circ Res"},{"key":"2026041214411615300_zwag182-B6","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.3390\/cells12121648","article-title":"A review of progress on targeting LDL receptor-dependent and -independent pathways for the treatment of hypercholesterolemia, a major risk factor of ASCVD","volume":"12","author":"Srivastava","year":"2023","journal-title":"Cells"},{"key":"2026041214411615300_zwag182-B7","doi-asserted-by":"crossref","first-page":"101708","DOI":"10.1016\/j.jacadv.2025.101708","article-title":"Treatment of homozygous familial hypercholesterolemia","volume":"4","author":"Cegla","year":"2025","journal-title":"JACC Adv"},{"key":"2026041214411615300_zwag182-B8","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/eurjpc\/zwae144","article-title":"Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary","volume":"31","author":"Gu","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026041214411615300_zwag182-B9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosissup.2014.07.005","article-title":"Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia","volume":"15","author":"Cuchel","year":"2014","journal-title":"Atheroscler Suppl"},{"key":"2026041214411615300_zwag182-B10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2018.06.859","article-title":"Familial hypercholesterolemia treatments: guidelines and new therapies","volume":"277","author":"Raal","year":"2018","journal-title":"Atherosclerosis"},{"key":"2026041214411615300_zwag182-B11","author":"Family Heart Foundation"},{"key":"2026041214411615300_zwag182-B12","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026041214411615300_zwag182-B13","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"key":"2026041214411615300_zwag182-B14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","article-title":"Overview of the current status of familial hypercholesterolaemia care in over 60 countries - the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"277","author":"Vallejo-Vaz","year":"2018","journal-title":"Atherosclerosis"},{"key":"2026041214411615300_zwag182-B15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"2026041214411615300_zwag182-B16","doi-asserted-by":"crossref","first-page":"118601","DOI":"10.1016\/j.atherosclerosis.2024.118601","article-title":"The German Lipoprotein Apheresis Registry\u2014summary of the eleventh annual report","volume":"398","author":"Schettler","year":"2024","journal-title":"Atherosclerosis"},{"key":"2026041214411615300_zwag182-B17","doi-asserted-by":"crossref","first-page":"117525","DOI":"10.1016\/j.atherosclerosis.2024.117525","article-title":"Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: an expert consensus statement from ERKNet and ESPN","volume":"392","author":"Reijman","year":"2024","journal-title":"Atherosclerosis"},{"key":"2026041214411615300_zwag182-B18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2352-4642(24)00073-7","article-title":"Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries","volume":"8","author":"Reijman","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"2026041214411615300_zwag182-B19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12887-022-03192-7","article-title":"Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia","volume":"22","author":"Lischka","year":"2022","journal-title":"BMC Pediatr"},{"key":"2026041214411615300_zwag182-B20","doi-asserted-by":"crossref","first-page":"103723","DOI":"10.1016\/j.numecd.2024.08.016","article-title":"Do genetically determined very high and very low LDL levels contribute to Lp(a) plasma concentration?","volume":"35","author":"Giammanco","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026041214411615300_zwag182-B21","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJM199005243222104","article-title":"Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia","volume":"322","author":"Seed","year":"1990","journal-title":"N Engl J Med"},{"key":"2026041214411615300_zwag182-B22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"2026041214411615300_zwag182-B23","author":"US Food and Drug Administration"},{"key":"2026041214411615300_zwag182-B24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"key":"2026041214411615300_zwag182-B25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jacl.2025.02.012","article-title":"Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: a new renaissance for the very young?","volume":"19","author":"Fornari","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026041214411615300_zwag182-B26","first-page":"410","article-title":"Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia","volume":"38","author":"Stirnkorb","year":"2025","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2026041214411615300_zwag182-B27","doi-asserted-by":"crossref","first-page":"118516","DOI":"10.1016\/j.atherosclerosis.2024.118516","article-title":"Compassionate use of evinacumab for the treatment of homozygous familial hypercholesterolaemia (HoFH) in children under 5 years of age: clinical experience","volume":"395","author":"McCrindle","year":"2024","journal-title":"Atherosclerosis"},{"key":"2026041214411615300_zwag182-B28","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/psp4.70017","article-title":"Comparison of model-predicted and observed evinacumab pharmacokinetics and efficacy in children aged &lt;5 years with homozygous familial hypercholesterolemia","volume":"14","author":"Bihorel","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026041214411615300_zwag182-B29","author":"European Medicines Agency"},{"key":"2026041214411615300_zwag182-B30","author":"Ultragenyx Japan K.K"},{"key":"2026041214411615300_zwag182-B31","author":"Ultragenyx Pharmaceutical Inc"},{"key":"2026041214411615300_zwag182-B32","author":"Regeneron Pharmaceuticals Inc"},{"key":"2026041214411615300_zwag182-B33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cjco.2021.11.009","article-title":"Treatment of homozygous familial hypercholesterolemia with evinacumab","volume":"4","author":"Jeraj","year":"2022","journal-title":"CJC Open"},{"key":"2026041214411615300_zwag182-B34","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurjpc\/zwae036","article-title":"Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry","volume":"31","author":"D'Erasmo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026041214411615300_zwag182-B35","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1016\/j.jacl.2024.05.006","article-title":"Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis","volume":"18","author":"Stefanutti","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026041214411615300_zwag182-B36","author":"Moriarty"},{"key":"2026041214411615300_zwag182-B37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/1744-9987.13856","article-title":"Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia","volume":"26","author":"Duell","year":"2022","journal-title":"Ther Apher Dial"},{"key":"2026041214411615300_zwag182-B38","doi-asserted-by":"crossref","first-page":"119234","DOI":"10.1016\/j.atherosclerosis.2025.119234","article-title":"Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C","volume":"406","author":"Nigmann","year":"2025","journal-title":"Atherosclerosis"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag182\/67603992\/zwag182.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag182\/67603992\/zwag182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T18:41:25Z","timestamp":1776019285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag182\/8551467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag182","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"zwag182"}}